Examples
Worked examples
- Is an instance
A clinical trial sponsor sizing an international Phase III development program for a chronic rheumatoid arthritis therapeutic to include 1,600 total subjects, with 500 completing 6 months and 120 completing 12 months of exposure per ICH E1 recommendations.
- Is an instance
A regulatory affairs team submitting a New Drug Application (NDA) to the FDA with complete 6-month safety exposure data and committing to supply 12-month exposure cohorts prior to marketing approval under ICH E1 guidance.
Counter-examples
Looks similar, but isn't
- Not an instance
Treating ICH E1 patient exposure thresholds as mandatory minimums for ultra-rare orphan drugs where the entire global target patient population is smaller than the recommended cohort sizes.
- Not an instance
Applying ICH E1 exposure minimums to short-term acute therapies (such as 7-day anti-infective regimens) rather than long-term or chronic maintenance medications.
Editorial commentary
Quick answer: ICH E1 (formally titled The Extent of Population Exposure to Assess Clinical Safety for Drugs Intended for Long-Term Treatment of Non-Life-Threatening Conditions) is an international regulatory guideline on the size and duration of patient exposure expected in a pre-approval clinical safety database. For drugs intended for chronic or repeated intermittent use for longer than 6 months, it anticipates about 1,500 patients treated in total, 300 to 600 patients treated for 6 months, and 100 patients exposed for a minimum of one year, at dosage levels intended for clinical use.
What ICH E1 Is and Who Regulates It
ICH E1 is an efficacy-family guideline of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). Its current Step 4 version is dated 27 October 1994, and it was recommended for adoption by the regulatory bodies of the European Union, Japan and the USA. The US Food and Drug Administration publishes it as guidance E1A (March 1995), and the European Medicines Agency publishes it as CPMP/ICH/375/95 (1995).
The guideline covers drugs intended for long-term treatment, meaning chronic or repeated intermittent use for longer than 6 months, of non-life-threatening diseases. It sits within the regulatory work of the pharmaceutical industry, and it is one input to the safety evaluation done during clinical development.
What Are the ICH E1 Population Exposure Numbers?
The guideline notes that most adverse drug events (ADEs) first occur, and are most frequent, within the first few months of treatment, but that some may increase in frequency or severity with time or appear only after more than 6 months. It therefore sets out three benchmarks for the safety database:
| Exposure Cohort | Duration | Patient Numbers | Purpose stated in the guideline |
|---|---|---|---|
| Total exposure | Including short-term exposure | About 1,500 patients | Overall size of the database; short-term event rates (cumulative 3-month incidence of about 1%) are expected to be well characterised. |
| Six-month exposure | 6 months | Usually 300 to 600 patients | Characterise the pattern of ADEs over time, including whether frequent events increase or decrease and delayed events in the general range of 0.5% to 5%. |
| One-year exposure | 12 months | 100 patients, minimum | Provide data on events that may appear only after prolonged treatment, from prospective studies at dosage levels intended for clinical use. |
The guideline states that safety evaluation during clinical development is not expected to characterise rare adverse events, for example those occurring in fewer than 1 in 1,000 patients. It also notes that Japan accepted 500 to 1,500 patients in total at the time, because of its post-marketing surveillance requirement.
Why Does ICH E1 Use 100 Patients for One Year?
ICH E1 describes the choice of a specific number of patients followed for one year as largely a judgement based on the probability of detecting a given ADE frequency and on practical considerations. It states that 100 patients exposed for a minimum of one year is considered acceptable, and that when no serious ADE is observed in that exposure period, this number of patients can provide reasonable assurance that the true cumulative one-year incidence is no greater than 3%.
When Does ICH E1 Not Apply as Written?
ICH E1 recognises that the harmonised general standard may not be applicable in some circumstances and lists exceptions:
- Larger or longer safety databases: where there is concern about late-developing ADEs or ADEs that increase in severity or frequency over time (based on animal data, related agents or pharmacologic classes, or pharmacokinetic or pharmacodynamic properties); where the occurrence rate of an expected low-frequency ADE needs to be quantified; where the benefit is small, experienced by only a fraction of patients, or of uncertain magnitude; or where the drug may add to an already significant background rate of morbidity or mortality.
- Smaller databases: in some cases a smaller number of patients may be acceptable, for example where the intended treatment population is small.
When Must 6-Month and 12-Month Data Be Submitted?
The guideline states that filing for approval will usually be possible based on data from patients treated through 6 months. Data on patients treated through 12 months must be submitted as soon as available and before approval in the United States and Japan, but may be submitted after approval in the European Community. In the US, the initial submission for drugs designated as priority drugs must include the 12-month patient data.
Sponsors planning clinical trial protocol design need to align study duration with these expectations, in coordination with regulatory affairs in the pharmaceutical industry. Good clinical practice expectations for the same trials are covered in ICH E6 vs ICH E8, ICH E6(R2), ICH E6(R3) and what changed in ICH E6(R3).
Frequently Asked Questions
What products does ICH E1 cover?
Drugs intended for long-term treatment of non-life-threatening diseases, defined in the guideline as chronic or repeated intermittent use for longer than 6 months.
What is the minimum number of patients treated for 1 year under ICH E1?
The guideline considers 100 patients exposed for a minimum of one year acceptable, with data from prospective studies at dosage levels intended for clinical use. If no serious ADE is observed, this gives reasonable assurance that the true cumulative one-year incidence is no greater than 3%.
Can a marketing application be filed before 12-month exposure data are complete?
Filing will usually be possible based on data through 6 months. In the United States and Japan the 12-month data must be submitted before approval, and in the US the initial submission for priority drugs must already include them.
Sources
- International Council for Harmonisation (ICH). “E1: The Extent of Population Exposure to Assess Clinical Safety for Drugs Intended for Long-Term Treatment of Non-Life-Threatening Conditions.” Step 4 version, 27 October 1994 (new codification November 2005). https://database.ich.org/sites/default/files/E1_Guideline.pdf (checked 2026-11-07).
- US Food and Drug Administration (FDA). “E1A The Extent of Population Exposure to Assess Clinical Safety: For Drugs Intended for Long-Term Treatment of Non-Life-Threatening Conditions,” March 1995. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e1a-extent-population-exposure-assess-clinical-safety-drugs-intended-long-term-treatment-non-life (checked 2026-11-07).
- European Medicines Agency (EMA). “ICH E1 Population exposure: the extent of population exposure to assess clinical safety,” CPMP/ICH/375/95. https://www.ema.europa.eu/en/scientific-guidelines/ich-e1-population-exposure-extent-population-exposure-assess-clinical-safety (checked 2026-11-07).
Machine-readable encodings
Use in your systems
<role vocab="credit"
vocab-identifier="https://casrai.org/dictionary/"
vocab-term="ICH E1: Population Exposure to Assess Clinical Safety"
vocab-term-identifier="https://casrai.org/dictionary/term/ich-e1" />{
"@context": "https://schema.org",
"@type": "DefinedTerm",
"@id": "https://casrai.org/dictionary/term/ich-e1",
"name": "ICH E1: Population Exposure to Assess Clinical Safety",
"identifier": "https://casrai.org/dictionary/term/ich-e1",
"description": "ICH E1 is the harmonized tripartite regulatory guideline titled \"The Extent of Population Exposure to Assess Clinical Safety for Drugs Intended for Long-Term Treatment of Non-Life-Threatening Conditions\". Formally adopted at Step 4 in October 1994, it defines pre-approval clinical safety database sizing standards for pharmaceuticals intended for chronic or repeated intermittent use exceeding 6 months. It establishes a baseline requirement of approximately 1,500 total patients, 300 to 600 patients followed for 6 months, and a minimum of 100 patients exposed continuously for at least 12 months at dosage levels intended for clinical practice.",
"inDefinedTermSet": "https://casrai.org/dictionary/domain/publishing#set",
"url": "https://casrai.org/dictionary/term/ich-e1",
"license": "https://creativecommons.org/licenses/by/4.0/",
"publisher": {
"@id": "https://casrai.org/#organization"
},
"author": {
"@id": "https://casrai.org/#editorial-team"
},
"datePublished": "2026-11-07T08:22:34",
"dateModified": "2026-11-07T08:39:48",
"inLanguage": "en-GB",
"isAccessibleForFree": true
}
